Strikingly, the AMPK-activating agents, metformin and AICAR have been shown to both attenuated cardiotoxicity and to reduce chemotherapy resistance [184] and proliferation [185] in human breast cancer cells and both AICAR and metformin can be safely administered alongside chemotherapy in patients [186, 187]. Here, PRKAA1 is linked to breast carcinoma.